Systemic Lupus Erythematosus 8

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 8

MalaCards integrated aliases for Systemic Lupus Erythematosus 8:

Name: Systemic Lupus Erythematosus 8 54
Systemic Lupus Erythematosus, Susceptibility to, 8 13


External Ids:

OMIM 54 610066

Summaries for Systemic Lupus Erythematosus 8

MalaCards based summary : Systemic Lupus Erythematosus 8, is also known as systemic lupus erythematosus, susceptibility to, 8. An important gene associated with Systemic Lupus Erythematosus 8 is SLEB8 (Systemic Lupus Erythematosus, Susceptibility To, 8). The drugs Mycophenolate mofetil and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include endothelial, skin and kidney.

Description from OMIM: 610066

Symptoms & Phenotypes for Systemic Lupus Erythematosus 8

Clinical features from OMIM:


Drugs & Therapeutics for Systemic Lupus Erythematosus 8

Drugs for Systemic Lupus Erythematosus 8 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
Sulfamethoxazole Approved Phase 4 723-46-6 5329
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
7 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
8 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
9 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
10 Hormone Antagonists Phase 4,Phase 3,Phase 2
11 Hormones Phase 4,Phase 3,Phase 2
12 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
13 Anti-Infective Agents Phase 4,Phase 2,Phase 1
14 Adrenocorticotropic Hormone Phase 4
15 beta-endorphin Phase 4
16 Melanocyte-Stimulating Hormones Phase 4
17 Antimalarials Phase 4
18 Antiparasitic Agents Phase 4
19 Antiprotozoal Agents Phase 4
20 Cytochrome P-450 Enzyme Inhibitors Phase 4
21 Folic Acid Antagonists Phase 4
22 Renal Agents Phase 4
23 Trimethoprim, Sulfamethoxazole Drug Combination Phase 4
24 Vitamin B Complex Phase 4
25 Folate Nutraceutical Phase 4
26 Vitamin B9 Nutraceutical Phase 4
27 Omega 3 Fatty Acid Nutraceutical Phase 4
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
31 Antiemetics Phase 3,Phase 2
32 Anti-Inflammatory Agents Phase 3,Phase 2
33 Antineoplastic Agents, Hormonal Phase 3,Phase 2
34 Antirheumatic Agents Phase 3,Phase 2,Phase 1
35 Autonomic Agents Phase 3,Phase 2
36 Gastrointestinal Agents Phase 3,Phase 2
37 glucocorticoids Phase 3,Phase 2
38 Methylprednisolone acetate Phase 3,Phase 2
39 Methylprednisolone Hemisuccinate Phase 3,Phase 2
40 Neuroprotective Agents Phase 3,Phase 2
41 Peripheral Nervous System Agents Phase 3,Phase 2
42 Prednisolone acetate Phase 3,Phase 2
43 Prednisolone hemisuccinate Phase 3,Phase 2
44 Prednisolone phosphate Phase 3,Phase 2
45 Protective Agents Phase 3,Phase 2,Phase 1
46 Pharmaceutical Solutions Phase 3,Phase 1
belimumab Approved Phase 2,Phase 1 356547-88-1 5957 10451420
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751

Interventional clinical trials:

(show top 50) (show all 60)

id Name Status NCT ID Phase Drugs
1 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
2 Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE) Completed NCT01101802 Phase 4 Mycophenolate mofetil;sugar pill
3 ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis Recruiting NCT01926054 Phase 4 Acthar gel
4 Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous Recruiting NCT03042260 Phase 4 Trimethoprim-Sulfamethoxazole;Placebo Oral Tablet
5 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Active, not recruiting NCT01753401 Phase 4 Acthar;Placebo for Acthar
6 Trial to Study the Effects of Supplementary Omega-3 on Serum C-Reactive Protein Levels Terminated NCT00578578 Phase 4
7 Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus Recruiting NCT03178188 Phase 2, Phase 3
8 Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis Suspended NCT01773616 Phase 3 Oral prednisolone;Rituximab;Mycophenolate mofetil;Methyl prednisolone
9 A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Patients With Systemic Lupus Erythematosus Terminated NCT01240694 Phase 3 Lupuzor
10 Study of LJP 394 in Lupus Patients With History of Renal Disease Terminated NCT00089804 Phase 3 abetimus sodium (LJP 394) and/or placebo solution;abetimus sodium (LJP 394);Phosphate-buffered saline
11 CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis Withdrawn NCT02074020 Phase 3 Blisibimod;Placebo
12 A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector Completed NCT02124798 Phase 2
13 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus Completed NCT00076752 Phase 2 fludarabine phosphate;cyclophosphamide;methylprednisolone;Diphenhydramine;Mesna
14 Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE) Completed NCT00997100 Phase 2 paquinimod (ABR-215757)
15 Vitamin D3 in Systemic Lupus Erythematosus Completed NCT00710021 Phase 2 Vitamin D3;Vitamin D3 placebo
16 Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors Completed NCT00519363 Phase 1, Phase 2 atorvastatin
17 Prospective Study of Rapamycin for the Treatment of SLE Completed NCT00779194 Phase 2 Rapamycin
18 Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus Completed NCT01405196 Phase 2
19 Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study Completed NCT00976300 Phase 2 Cyclosporine A;Cyclophosphamide
20 Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease Completed NCT00624351 Phase 2
21 Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects Completed NCT01534403 Phase 2
22 A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus. Completed NCT01031836 Phase 2 MEDI-545;MEDI-545;MEDI-545;MEDI-545;MEDI-545;MEDI-545 600
23 PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus Completed NCT01162681 Phase 2 A-623;A-623;A-623
24 Pilot Study of Thalidomide to Treat Sjogren's Syndrome Completed NCT00001599 Phase 2 Thalidomide
25 Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus Recruiting NCT03288324 Phase 1, Phase 2 Tofacitinib
26 Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE) Recruiting NCT02338999 Phase 1, Phase 2 Pioglitazone
27 Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Recruiting NCT02847598 Phase 2 BIIB059;Placebo
28 A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus Active, not recruiting NCT02349061 Phase 2 Ustekinumab IV;Placebo Infusion;Placebo SC;Ustekinumab SC
29 Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus Active, not recruiting NCT02554019 Phase 2
30 Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Patients Who Participated in ADDRESS II) Active, not recruiting NCT02070978 Phase 2 Atacicept 75 mg;Atacicept 150 mg
31 Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine Suspended NCT00775476 Phase 1, Phase 2 N-acetylcysteine;N-acetylcysteine;Placebo
32 Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC) Terminated NCT01738360 Phase 2 Arsenic trioxide
33 An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 Terminated NCT01777256 Phase 2 GSK2586184 50 mg;GSK2586184 100 mg;GSK2586184 200 mg;GSK2586184 400 mg;Placebo
34 Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant Terminated NCT01025193 Phase 2 Belimumab
35 Physical Activity in Patients With Systemic Lupus Erythematosus Unknown status NCT00985803 Phase 1
36 Humanized LL2IGG to Treat Systemic Lupus Erythematosus Completed NCT00011908 Phase 1 hLL2 (Epratuzumab)
37 Safety Study of AMG 557 in Subjects With Lupus Arthritis Completed NCT01683695 Phase 1 AMG 557;Matching Placebo
38 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE) Completed NCT01686555 Phase 1 ABT-199
39 Cyclophosphamide and Fludarabine to Treat Lupus Nephritis Completed NCT00001676 Phase 1 SQ Fludarabine
40 Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE) Completed NCT00657007 Phase 1
41 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 in Healthy Volunteers and Participants With Systemic Lupus Erythematosus Completed NCT02106897 Phase 1 BIIB059;Placebo
42 Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE) Completed NCT01093911 Phase 1
43 Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects Completed NCT02151409 Phase 1 NNC 0151-0000-0000;NNC 0151-0000-0000;placebo
44 A Phase I Study of ICP-022 in Subjects Recruiting NCT03189017 Phase 1 ICP-022;Placebos
45 Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome Terminated NCT02741362 Phase 1
46 Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc) Terminated NCT00684255 Phase 1 Fludarabine;Busulfan;Campath
47 Hematopoietic Stem Cell Support in Vasculitis Terminated NCT00278512 Phase 1
48 Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus Terminated NCT01164917 Phase 1 AMG811;AMG811 Placebo
49 International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus Completed NCT01509989
50 GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus Completed NCT01992666

Search NIH Clinical Center for Systemic Lupus Erythematosus 8

Genetic Tests for Systemic Lupus Erythematosus 8

Anatomical Context for Systemic Lupus Erythematosus 8

MalaCards organs/tissues related to Systemic Lupus Erythematosus 8:

Endothelial, Skin, Kidney, Heart, Bone

Publications for Systemic Lupus Erythematosus 8

Variations for Systemic Lupus Erythematosus 8

Expression for Systemic Lupus Erythematosus 8

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 8.

Pathways for Systemic Lupus Erythematosus 8

GO Terms for Systemic Lupus Erythematosus 8

Sources for Systemic Lupus Erythematosus 8

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
66 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....